Biologic and Small Molecule Drug Development

We are currently seeking Senior Research Fellows/ Academic Level C – join us as we strengthen our drug discovery research program. Apply now.

Apply Now

Structural biology–guided drug discovery is now considered an essential and widespread approach in the pharmaceutical industry. Structural biology is underpinned by techniques such as X-ray crystallography, nuclear magnetic resonance and, more recently, cryo-electron microscopy, and reveals the 3D atomic structures of proteins that play key roles in health and disease. The concept of rational drug design using the 3D structures of proteins is widely accepted by the pharmaceutical industry: there is an estimated 50 per cent cost and time saving from target selection to investigational new drug filing when structure determination is used centrally within the drug discovery process.

Recently, an alliance of like-minded academic institutions and industry in the Melbourne Biomedical Precinct has come together with a vision to develop a drug discovery hub that aspires to rival leading hubs internationally.

The University of Melbourne and its partners are major players in rational drug discovery and development in Australia. Recent examples include:

  • the University spin off, Fibrotech, which developed an antifibrotic drug, purchased by Shire in 2014 for over $80 million;
  • CTx which developed PRMT5 inhibitors, licensed to Merck in a deal worth up to $730 million;
  • and WEHI in a US$325 million deal, collaborated with Genentech and AbbVie to develop the anti-cancer drug Venetoclax.

The University of Melbourne is seeking new researchers at academic level C who can join in and benefit from our developing critical mass of research talent and facilities for drug discovery research. We are seeking researchers with demonstrated expertise to build an internationally competitive research program in:

  • x-ray crystallography and drug design
  • NMR and drug discovery
  • cryo electron microscopy and drug design
  • computational biology and drug discovery
  • mass spectrometry and drug development

Applications are open until 24th July 2018 and will require a:

For enquiries please email: mdhs-campaign@unimelb.edu.au

Apply Now

Key partners, schools and centres at the University of Melbourne involved in early stage drug discovery research:

School of Biomedical Sciences

School of Chemistry

School of Biosciences

Melbourne Dental School

Melbourne School of Engineering

Bio21 Molecular Science & Biotechnology Institute

The Peter Doherty Institute for Infection and Immunity

The Murdoch Children's Research Institute

The Victorian Comprehensive Cancer Centre

The Florey Institute of Neuroscience and Mental Health

The Walter and Eliza Hall Institute of Medical Research

The Peter MacCallum Cancer Centre

Monash Institute of Pharmaceutical Sciences

The Melbourne Biomedical Precinct

Biocurate

Cetara

CSL

Cancer Therapeutics CRC (CTX)

SynThesis